50
References:
1.
Gariano RF, Gardner TW. Retinal angiogenesis in development
and disease. Nature 2005; 438 (7070): 960-966.
2.
Costa C, Incio J, Soares R. Angiogenesis and chronic inflamma-
tion: cause or consequence? Angiogenesis 2007; 10 (3): 149-166.
3.
Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Na-
ture 2005; 438 (7070): 967-974.
4.
Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ,
Holash J. Vascular-specific growth factors and blood vessel for-
mation. Nature 2000; 407 (6801): 242-248.
5.
Presta M, Dell’Era P, Mitola S, Moroni E, Ronca R, Rusnati
M. Fibroblast growth factor/fibroblast growth factor receptor
system in angiogenesis. Cytokine Growth Factor Rev 2005; 16
(2): 159-178.
6.
Miyazono K, Usuki K, Heldin CH. Platelet-derived endothelial
cell growth factor. Prog Growth Factor Res 1991; 3 (3): 207-217.
7.
Luttun A, Tjwa M, Carmeliet P. Placental growth factor (PlGF)
and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for
angiogenic disorders. Ann N Y Acad Sci 2002; 979: 80-93.
8.
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its
receptors. Nat Med 2003; 9 (6): 669-676.
9.
Ohnishi T, Daikuhara Y. Hepatocyte growth factor/scatter factor
in development, inflammation and carcinogenesis: its expression
and role in oral tissues. Arch Oral Biol 2003; 48 (12): 797-804.
10.
Ferrara N, Damico L, Shams N, Lowman H, Kim R. Develop-
ment of ranibizumab, an anti-vascular endothelial growth factor
antigen binding fragment, as therapy for neovascular age-related
macular degeneration. Retina 2006; 26 (8): 859-870.
11.
Ferrara N, Mass RD, Campa C, Kim R. Targeting VEGF-A to
treat cancer and age-related macular degeneration. Annu Rev
Med 2007; 58: 491-504.
12.
Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I,
Schmitt FC. Cyclo-oxygenase 2 expression is associated with an-
giogenesis and lymph node metastasis in human breast cancer. J
Clin Pathol 2002; 55 (6): 429-434.
13.
Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a ther-
apy for life-threatening hemangiomas of infancy. N Engl J Med
1992; 326 (22): 1456-1463.
14.
Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ,
Bouck N. Peptides derived from two separate domains of the
matrix protein thrombospondin-1 have anti-angiogenic activity.
J Cell Biol 1993; 122 (2): 497-511.
15.
O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS,
Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an
endogenous inhibitor of angiogenesis and tumor growth. Cell
1997; 88 (2): 277-285.
16.
O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA,
Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin:
a novel angiogenesis inhibitor that mediates the suppression of
metastases by a Lewis lung carcinoma. Cell 1994; 79 (2): 315-
328.
17.
Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Bene-
dict W, Bouck NP. Pigment epithelium-derived factor: a potent
inhibitor of angiogenesis. Science 1999; 285 (5425): 245-248.
18.
Dorrell M, Uusitalo-Jarvinen H, Aguilar E, Friedlander M.
Ocular neovascularization: basic mechanisms and therapeutic
advances. Surv Ophthalmol 2007; 52 (Suppl. 1): S3-S19.
19.
Gariano RF. Cellular mechanisms in retinal vascular develop-
ment. Prog Retin Eye Res 2003; 22 (3): 295-306.
20.
Chan-Ling T, McLeod DS, Hughes S, Baxter L, Chu Y, Hasega-
wa T, Lutty GA. Astrocyte-endothelial cell relationships during
human retinal vascular development. Invest Ophthalmol Vis Sci
2004; 45 (6): 2020-2032.
21.
Lutty GA, Chan-Ling T, Phelps DL, Adamis AP, Berns KI, Chan
CK, Cole CH, D’Amore PA, Das A, Deng WT, Dobson V, Fly-
nn JT, Friedlander M, Fulton A, Good WV et al. Proceedings of
the Third International Symposium on Retinopathy of Prematu-
rity: an update on ROP from the lab to the nursery (November
2003, Anaheim, California). Mol Vis 2006; 12: 532-580.
22.
Hughes S, Yang H, Chan-Ling T. Vascularization of the human
fetal retina: roles of vasculogenesis and angiogenesis. Invest Oph-
thalmol Vis Sci 2000; 41 (5): 1217-1228.
23.
Chan-Ling T, Gock B, Stone J. The effect of oxygen on vasofor-
mative cell division. Evidence that ‘physiological hypoxia’ is the
stimulus for normal retinal vasculogenesis. Invest Ophthalmol
Vis Sci 1995; 36 (7): 1201-1214.
24.
Cunha-Vaz JG. The blood-retinal barriers system. Basic concepts
and clinical evaluation. Exp Eye Res 2004; 78 (3): 715-721.
25.
Eichler W, Yafai Y, Wiedemann P, Fengler D. Antineovascular
agents in the treatment of eye diseases. Curr Pharm Des 2006;
12 (21): 2645-2660.
26.
Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G,
Davis MD, de Jong PT, Klaver CC, Klein BE, Klein R. An inter-
national classification and grading system for age-related macu-
lopathy and age-related macular degeneration. The International
ARM Epidemiological Study Group. Surv Ophthalmol 1995; 39
(5): 367-374.
27.
Hogg RE, Chakravarthy U. Visual function and dysfunction in
early and late age-related maculopathy. Prog Retin Eye Res 2006;
25 (3): 249-276.
28.
de Jong PT. Age-related macular degeneration. N Engl J Med
2006; 355 (14): 1474-1485.
29.
Andreoli CM, Miller JW. Anti-vascular endothelial growth fac-
tor therapy for ocular neovascular disease. Curr Opin Ophthal-
mol 2007; 18 (6): 502-508.
30.
Shibuya M. Structure and function of VEGF/VEGF-receptor
system involved in angiogenesis. Cell Struct Funct 2001; 26 (1):
25-35.
31.
Ng EW, Adamis AP. Targeting angiogenesis, the underlying dis-
order in neovascular age-related macular degeneration. Can J
Ophthalmol 2005; 40 (3): 352-368.
32.
Semenza GL. Vasculogenesis, angiogenesis, and arteriogenesis:
mechanisms of blood vessel formation and remodeling. J Cell
Biochem 2007; 102 (4): 840-847.
